Healthcare provider profile · identity verified

Aviva Iofel, MD

Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1619918182

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Aviva Iofel, MD received $111.63 in general payments during 2025 across 5 reported records.

Lilly USA, LLC accounted for 30.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 5 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Trulance.

Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.

Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulance by this doctor in 2024.

Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Gemtesa by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$111.63

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$34.32	30.7%	1	2025
Amgen Inc.	Unresolved — no canonical attribution shown	$28.50	25.5%	2	2025
Sumitomo Pharma America, Inc.	Unresolved — no canonical attribution shown	$27.27	24.4%	1	2025
Salix Pharmaceuticals, a division of Bausch Health US, LLC	Unresolved — no canonical attribution shown	$21.54	19.3%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$111.63	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
MOUNJARO Normalized: mounjaro	Drug	Lilly USA, LLC	$34.32	1	2025
Source payment records 2025-03-20 · Lilly USA, LLC · $34.32 · Open Payments source
ZEPBOUND Normalized: zepbound	Drug	Lilly USA, LLC	$34.32	1	2025
Source payment records 2025-03-20 · Lilly USA, LLC · $34.32 · Open Payments source
REPATHA Normalized: repatha	Biological	Amgen Inc.	$28.50	2	2025
Source payment records 2025-05-15 · Amgen Inc. · $14.25 · Open Payments source 2025-06-13 · Amgen Inc. · $14.25 · Open Payments source
GEMTESA Normalized: gemtesa	Drug	Sumitomo Pharma America, Inc.	$27.27	1	2025
Source payment records 2025-08-06 · Sumitomo Pharma America, Inc. · $27.27 · Open Payments source
TRULANCE Normalized: trulance	Drug	Salix Pharmaceuticals, a division of Bausch Health US, LLC	$21.54	1	2025
Source payment records 2025-06-30 · Salix Pharmaceuticals, a division of Bausch Health US, LLC · $21.54 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
GEMTESA gemtesa	2025	Gemtesa	2024	44 Beneficiary count suppressed	exact normalized	Medicare Part D
MOUNJARO mounjaro	2025	Mounjaro	2024	36	exact normalized	Medicare Part D
TRULANCE trulance	2025	Trulance	2024	38 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Amgen Inc. Exact reporting entity; no affiliate inference	2025	PROLIA open payments reported associated product	CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448	Prolia · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	51	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	36	11
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference	2025	TRULANCE open payments reported associated product	CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445	Trulance · 2024 Exact normalized brand match · 1 Part D row	38	suppressed by CMS
Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference	2025	GEMTESA open payments reported associated product	CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503	Gemtesa · 2024 Exact normalized brand match · 1 Part D row	44	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	1149	158
Rosuvastatin Calcium	Rosuvastatin Calcium	1010	135
Levothyroxine Sodium	Levothyroxine Sodium	599	66
Metoprolol Succinate	Metoprolol Succinate	463	67
Metformin Hcl	Metformin Hcl	416	53
Dexlansoprazole Dr	Dexlansoprazole	403	55
Olmesartan Medoxomil	Olmesartan Medoxomil	397	55
Gabapentin	Gabapentin	394	45
Famotidine	Famotidine	368	45
Atorvastatin Calcium	Atorvastatin Calcium	364	57
Hydralazine Hcl	Hydralazine Hcl	332	44
Pantoprazole Sodium	Pantoprazole Sodium	325	53
Creon	Lipase/Protease/Amylase	301	42
Ezetimibe	Ezetimibe	300	36
Omeprazole	Omeprazole	290	40
Diclofenac Epolamine	Diclofenac Epolamine	275	27
Meloxicam	Meloxicam	275	43
Telmisartan	Telmisartan	263	35
Losartan Potassium	Losartan Potassium	255	37
Meclizine Hcl	Meclizine Hcl	255	31
Icosapent Ethyl	Icosapent Ethyl	251	33
Esomeprazole Magnesium	Esomeprazole Magnesium	250	37
Escitalopram Oxalate	Escitalopram Oxalate	247	32
Linzess	Linaclotide	241	39
Allopurinol	Allopurinol	235	30
Azelastine Hcl	Azelastine Hcl	231	49
Furosemide	Furosemide	229	31
Tramadol Hcl	Tramadol Hcl	229	34
Nebivolol Hcl	Nebivolol Hcl	222	27
Janumet	Sitagliptin Phos/Metformin Hcl	216	27
Omeprazole-Sodium Bicarbonate	Omeprazole/Sodium Bicarbonate	206	19
Ozempic	Semaglutide	187	24
Zolpidem Tartrate	Zolpidem Tartrate	187	24
Potassium Chloride	Potassium Chloride	181	22
Lidocaine	Lidocaine	171	23
Glimepiride	Glimepiride	170	22
Celecoxib	Celecoxib	163	19
Clonazepam	Clonazepam	163	23
Trazodone Hcl	Trazodone Hcl	163	26
Clopidogrel	Clopidogrel Bisulfate	161	19
Tamsulosin Hcl	Tamsulosin Hcl	157	22
Simvastatin	Simvastatin	151	19
Dapagliflozin	Dapagliflozin Propanediol	149	24
Diclofenac Sodium	Diclofenac Sodium	147	30
Atenolol	Atenolol	132	18
Hydrochlorothiazide	Hydrochlorothiazide	125	16
Alendronate Sodium	Alendronate Sodium	123	13
Baclofen	Baclofen	117	22
Montelukast Sodium	Montelukast Sodium	116	12
Sertraline Hcl	Sertraline Hcl	115	13
Carvedilol	Carvedilol	114	16
Duloxetine Hcl	Duloxetine Hcl	111	13
Captopril	Captopril	105	14
Edarbyclor	Azilsartan Med/Chlorthalidone	102	13
Solifenacin Succinate	Solifenacin Succinate	100	suppressed
Farxiga	Dapagliflozin Propanediol	95	20
Synthroid	Levothyroxine Sodium	95	13
Doxepin Hcl	Doxepin Hcl	93	11
Ketoconazole	Ketoconazole	90	13
Xarelto	Rivaroxaban	89	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	88	16
Enalapril Maleate	Enalapril Maleate	85	suppressed
Metformin Hcl Er	Metformin Hcl	85	14
Memantine Hcl	Memantine Hcl	84	12
Eliquis	Apixaban	83	13
Ropinirole Hcl	Ropinirole Hcl	83	suppressed
Temazepam	Temazepam	82	11
Nitroglycerin	Nitroglycerin	77	15
Lisinopril	Lisinopril	75	14
Dicyclomine Hcl	Dicyclomine Hcl	73	12
Metoprolol Tartrate	Metoprolol Tartrate	73	11
Triamcinolone Acetonide	Triamcinolone Acetonide	73	17
Donepezil Hcl	Donepezil Hcl	72	suppressed
Pregabalin	Pregabalin	72	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	72	suppressed
Lactulose	Lactulose	69	14
Repatha Sureclick	Evolocumab	69	suppressed
Vascepa	Icosapent Ethyl	69	16
Colchicine	Colchicine	67	suppressed
Azithromycin	Azithromycin	66	58
Febuxostat	Febuxostat	66	suppressed
Lorazepam	Lorazepam	66	13
Venlafaxine Hcl Er	Venlafaxine Hcl	66	suppressed
Clonidine Hcl	Clonidine Hcl	64	suppressed
Spironolactone	Spironolactone	64	suppressed
Metformin Er Gastric	Metformin Hcl	63	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	60	suppressed
Myrbetriq	Mirabegron	60	suppressed
Fluticasone Propionate	Fluticasone Propionate	59	suppressed
Propranolol Hcl	Propranolol Hcl	58	suppressed
Hydrocortisone	Hydrocortisone	57	13
Isosorbide Mononitrate Er	Isosorbide Mononitrate	54	suppressed
Dexilant	Dexlansoprazole	53	suppressed
Econazole Nitrate	Econazole Nitrate	53	suppressed
Ibuprofen	Ibuprofen	53	12
Jardiance	Empagliflozin	51	suppressed
Clonidine	Clonidine	50	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	50	suppressed
Tradjenta	Linagliptin	50	suppressed
Pravastatin Sodium	Pravastatin Sodium	49	suppressed
Tavaborole	Tavaborole	49	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	48	suppressed
Mirtazapine	Mirtazapine	48	suppressed
Procto-Med Hc	Hydrocortisone	47	suppressed
Entresto	Sacubitril/Valsartan	44	suppressed
Gemtesa	Vibegron	44	suppressed
Januvia	Sitagliptin Phosphate	43	suppressed
Benazepril Hcl	Benazepril Hcl	42	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	42	suppressed
Irbesartan	Irbesartan	42	suppressed
Metformin Er Osmotic	Metformin Hcl	42	suppressed
Nexium	Esomeprazole Magnesium	42	suppressed
Nystatin	Nystatin	42	14
Nystatin-Triamcinolone	Nystatin/Triamcinolone Acet	42	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	42	suppressed
Buspirone Hcl	Buspirone Hcl	40	suppressed
Clotrimazole	Clotrimazole	40	suppressed
Dutasteride	Dutasteride	40	suppressed
Glipizide	Glipizide	40	suppressed
Sucralfate	Sucralfate	40	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	39	suppressed
Jentadueto	Linagliptin/Metformin Hcl	39	suppressed
Amiodarone Hcl	Amiodarone Hcl	38	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Eszopiclone	Eszopiclone	38	11
Trulance	Plecanatide	38	suppressed
Digoxin	Digoxin	36	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	suppressed
Mounjaro	Tirzepatide	36	11
Constulose	Lactulose	35	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	31	suppressed
Olmesartan-Amlodipine-Hctz	Olmesartan/Amlodipin/Hcthiazid	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Lansoprazole	Lansoprazole	30	suppressed
Memantine Hcl Er	Memantine Hcl	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Risedronate Sodium	Risedronate Sodium	30	suppressed
Zenpep	Lipase/Protease/Amylase	30	suppressed
Diflorasone Diacetate	Diflorasone Diacetate	29	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Valsartan	Valsartan	27	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	26	22
Armour Thyroid	Thyroid,pork	24	suppressed
Nifedipine Er	Nifedipine	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Valacyclovir	Valacyclovir Hcl	24	suppressed
Alprazolam	Alprazolam	23	suppressed
Benicar	Olmesartan Medoxomil	23	suppressed
Bystolic	Nebivolol Hcl	23	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	23	suppressed
Crestor	Rosuvastatin Calcium	23	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	23	suppressed
Fluconazole	Fluconazole	21	13
Fluocinonide	Fluocinonide	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	21	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	21	suppressed
Prednisone	Prednisone	21	suppressed
Edarbi	Azilsartan Medoxomil	20	suppressed
Fenofibrate	Fenofibrate	20	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Meloxicam	Meloxicam, Submicronized	20	suppressed
Repaglinide	Repaglinide	20	suppressed
Mupirocin	Mupirocin	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Ranolazine Er	Ranolazine	18	suppressed
Zaleplon	Zaleplon	18	suppressed
Ibandronate Sodium	Ibandronate Sodium	17	suppressed
Methocarbamol	Methocarbamol	17	suppressed
Modafinil	Modafinil	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	12
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	16	suppressed
Cephalexin	Cephalexin	16	14
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Trintellix	Vortioxetine Hydrobromide	16	suppressed
Cyclosporine	Cyclosporine	15	suppressed
Enulose	Lactulose	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	14	suppressed
Chlorthalidone	Chlorthalidone	14	suppressed
Lovastatin	Lovastatin	14	suppressed
Pitavastatin Calcium	Pitavastatin Calcium	14	suppressed
Praluent Pen	Alirocumab	14	suppressed
Restasis	Cyclosporine	14	suppressed
Rybelsus	Semaglutide	14	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	13	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	13	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	13	suppressed
Calcium Acetate	Calcium Acetate	13	suppressed
Ciclopirox	Ciclopirox Olamine	13	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	13	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	13	suppressed
Prolia	Denosumab	13	suppressed
Propylthiouracil	Propylthiouracil	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Terconazole	Terconazole	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Chlorzoxazone	Chlorzoxazone	12	suppressed
Finasteride	Finasteride	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Letrozole	Letrozole	12	suppressed
Mesalamine Dr	Mesalamine	12	suppressed
Mirabegron Er	Mirabegron	12	suppressed
Nateglinide	Nateglinide	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Risedronate Sodium Dr	Risedronate Sodium	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$111.63 · 5 records	Lilly USA, LLC	GEMTESA, MOUNJARO, REPATHA, TRULANCE, ZEPBOUND	6	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Gemtesa play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error